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ABSTRACT
The 26S proteasome at the center of the ubiquitin-
proteasome system (UPS) is essential for virtually all
cellular processes of eukaryotes. A common miscon-
ception about the proteasome is that, once made, it
remains as a static and uniform complex with sponta-
neous and constitutive activity for protein degradation.
Recent discoveries have provided compelling evidence
to support the exact opposite insomuch as the 26S
proteasome undergoes dynamic and reversible phos-
phorylation under a variety of physiopathological con-
ditions. In this review, we summarize the history and
current understanding of proteasome phosphorylation,
and advocate the idea of targeting proteasome kinases/
phosphatases as a new strategy for clinical interven-
tions of several human diseases.
KEYWORDS proteasome, phosphorylation, kinase,
phosphatase, protein degradation
INTRODUCTION
The year of 2017 marks the 30th anniversary of the dis-
covery of proteasome, the central hub of protein degradation
in all eukaryotic cells (Hough et al., 1987; Waxman et al.,
1987). The past three decades have witnessed enormous
advancement of our understanding about proteasomal
degradation of proteins involved in almost every aspect of
cell biology. The biological importance, biochemical com-
plexity, and clinical relevance of the proteasome system are
now well established, although many important details of
proteasome function, structure, and regulation remain elu-
sive and will continue to be topics of intensive research
(Finley, 2009; Schmidt and Finley, 2014; Finley et al., 2016;
Livneh et al., 2016).
The core of all proteasome complexes is a 28-subunit,
barrel-shaped structure known as the 20S proteasome or
core particle (20S CP). These subunits are arranged as four
stacked rings (Groll et al., 1997; Unno et al., 2002). The two
outer rings (at the top and bottom of the CP) are made of α
subunits (α1–7, designated PSMAs in human and higher
eukaryotes), whose N-termini form a “gate” at the axial
center and occlude the entrance into the CP chamber. Each
of the two inner rings is composed of subunits β1–7
(PSMBs). Three of the β subunits, namely β1, β2 and β5,
function as threonine-proteases and preferentially cleave
substrate polypepetides after acidic (caspase-like activity),
basic (trypsin-like activity), and hydrophobic residues (chy-
motrypsin-like activity), respectively. All their N-terminal
active sites are positioned at the interior center of the CP. In
addition to these constitutive subunits, the CP can incorpo-
rate specialized subunits such as β1i, β2i, and β5i to form
immunoproteasomes (Kloetzel, 2001), or β5t to form thy-
moproteasomes (Murata et al., 2007), or α4s instead of α4 in
the testis (Uechi et al., 2014). Due to its unique architecture,
the 20S proteasome in its free form cannot degrade folded
protein substrates as they are inaccessible to the catalytic
center.
For proteasomal degradation to occur, the gate formed by
α subunits must be opened to allow for substrate entry. This
“gate-opening” function can be achieved by several types of
proteasome activators that directly bind the α ring, including
the 19S regulatory particle (RP)/PA700, 11S/PA28/REG, and
Blm10/PA200 (Stadtmueller and Hill, 2011). Thus, different
forms of CP may associate with different activators, resulting
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in multiple types of proteasome complexes that co-exist in
cells. The 19S RP has been widely studied and together with
20S CP forms the best known 26S proteasome, a 2.0–2.5
MDa machinery that degrades the vast majority of poly-
ubiquitinated as well as some non-ubiquitinated proteins of
the cell (Finley, 2009).
A total of nineteen subunits assemble into the 19S RP,
including six AAA+ type ATPases (Rpt1–6, or PSMCs) and
thirteen non-ATPase proteins (Rpn1–3, 5–13 and 15, known
as PSMDs). Each Rpt subunit contains an N-terminal ﬂexible
region, a coiled-coil domain, an oligonucleotide-binding (OB)
domain and an ATPase domain. The coiled-coil regions are
required for dimerization of Rpt1-Rpt2, Rpt3-Rpt6, and Rpt4-
Rpt5, which join with one another in the presence of multiple
assembly chaperones to form a hexameric ATPase ring that
directly caps one or both ends of the CP (Funakoshi et al.,
2009; Kaneko et al., 2009; Murata et al., 2009; Park et al.,
2009; Roelofs et al., 2009; Yu et al., 2010). In the Rpt ring
structure, the OB and ATPase domains make up the central
channel, which upon substrate polypeptide binding aligns
with the CP gate to form a continuous passage. Substrate
engagement with Rpts also stimulates their ATPase activity
that in turn provides the necessary energy for substrate
unfolding before its translocation to the CP (Smith et al.,
2005; Peth et al., 2013). The extreme C-termini of Rpt2, 3,
and 5 contain a HbYX motif (hydrophobic residue-tyrosine-
any amino acid). They play critical roles in RP-CP interaction
by directly inserting into pockets of the α ring, at the same
time causing signiﬁcant conformational changes and open-
ing of the CP gate (Smith et al., 2007; Rabl et al., 2008; Park
et al., 2009). The coiled-coil, OB, ATPase domains and the
HbYX motif are well deﬁned in crystal and cryo-EM struc-
tures, and their primary sequences are highly conserved
through evolution (Djuranovic et al., 2009; Chen et al., 2016;
Huang et al., 2016; Schweitzer et al., 2016). On the other
hand, the extreme N-termini of Rpts appear to be poorly
structured and less conserved, although they harbor modi-
ﬁcation sites that are important for modulating proteasome
functions (See later).
Rpt1–6 and three non-ATPase subunits (Rpn1, 2, and 13)
are traditionally referred to as the “base” of the 19S RP, while
the remaining Rpn subunits constitute the “lid”. In the cyro-
EM models, Rpn2 is positioned at the apex of the 26S
holoenzyme (farthest from the 20S CP) and directly contacts
the coiled-coils of Rpt3-Rpt6. The latter serves as a pivot
around which the lid complex rotates in accord with substrate
engagement, unfolding, and translocation (Matyskiela et al.,
2013; Unverdorben et al., 2014). Rpn1, Rpn10, and Rpn13
function as receptors for ubiquitin and ubiquitin-like (UBL)
domain proteins (Deveraux et al., 1995; Husnjak et al., 2008;
Schreiner et al., 2008; Shi et al., 2016). The proteasome-
intrinsic de-ubiquitinating enzyme Rpn11 and its partner
Rpn8 cleave off ubiquitin chains from committed protein
substrates in order to facilitate substrate unfolding, translo-
cation, and ubiquitin recycling (Verma et al., 2002; Yao and
Cohen, 2002; Worden et al., 2014). The rest of RP subunits
(Rpn3, 5, 6, 7, 9, 12, 15) are not known to possess enzy-
matic or receptor properties but play essential structural
functions in 26S proteasome assembly. Working as a com-
plex, the 19S RP is responsible for (i) substrate recognition
and engagement, (ii) substrate de-ubiquitination, (iii) sub-
strate unfolding and translocation, and (iv) 20S gate opening
and activation. Of note, all these activities except for sub-
strate recognition depend on ATP binding/hydrolysis by the
ATPase subunits. Therefore, Rpt1–6 play structural, enzy-
matic, and regulatory roles that are essential for 26S pro-
teasome function (Finley, 2009; Ehlinger and Walters, 2013).
The assembly of individual subunits into a functional
proteasome is controlled by a series of chaperone proteins,
representing the best characterized aspect of proteasome
regulation (Murata et al., 2009). Most chaperones are
absent/dislodged from the fully assembled complex, while
dozens to hundreds of other cellular proteins can dynami-
cally interact with the mature proteasome (Wang et al., 2007;
Wang and Huang, 2008). Although the biological meanings
of these interactions are largely unknown, many protea-
some-interacting proteins (PIPs) have enzymatic activities
and modify the proteasome in a variety of ways (reviewed by
Scruggs et al., 2012; Cui et al., 2014). Not surprisingly,
phosphorylation is one of the most frequent and better
studied means of post-translational modiﬁcation of the
proteasome.
In this review, we summarize our current understanding of
proteasome regulation by reversible phosphorylation. Due to
space limit, we only focus on phosphorylations of integral
subunits of the constitutive human 26S proteasome (We will
adhere to the nomenclature of α1–7, β1–7, Rpt1–6, and Rpns
to avoid confusion) and highlight the functions of selected
kinases/phosphatases and phosphosites (Fig. 1). We also
discuss technical issues and potential clinical applications of
present research on proteasome phosphoregulation.
OVERVIEW OF 26S PROTEASOME
PHOSPHORYLATION
The ﬁrst documentation of proteasome phosphorylation
dates back to 1989, not long after the discovery of the pro-
teasome itself, when Haass and Kloetzel reported that pro-
teasome subunits were modiﬁed (phosphorylated) in
Drosophila cells. These researchers insightfully argued that
“the in vivo proteolytic activity and the in vivo substrate
speciﬁcity of the proteasome may be regulated by modiﬁ-
cation of its subunit composition during ﬂy development”
(Haass and Kloetzel, 1989). Their observations have now
been supported by ﬁner proteomic studies of many organ-
isms, and yet the biological signiﬁcance of proteasome
phosphorylation during development is, by and large, still a
mystery.
In the following decade, numerous independent reports
had demonstrated phosphorylations of different proteasome
subunits with limited information on their function.
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Phosphorylation was even once considered to partly
account for the ATP-dependence of proteasome function
(Ludemann et al., 1993). Some of the early studies reached
inconsistent and occasionally contradictory conclusions as
to which subunits were phosphorylated on which sites, lar-
gely due to differences among cell types (with distinct
expression and activity of kinases/phosphatases), species
(with or without a non-conserved phosphosite), and puriﬁ-
cation procedures (Labile phosphorylations are easily lost
during lengthy chromatography or in the absence of phos-
phatase inhibitors). Moreover, it was very difﬁcult, if not
entirely impossible, to determine the exact phosphorylation
sites of a gigantic protein complex like the proteasome
simply by 32P labeling, 2D-electrophoresis, and phospho-
amino acid mapping. In fact, phosphorylations detected by
these methods were either highly abundant in a particular
cell/tissue type, or fairly resistant to dephosphorylation, or
possibly artifacts of proteasome puriﬁcation and in vitro
kinase reactions.
The advent of tandem mass spectrometry (MS/MS)-
based phosphoproteomics caused revolutionary changes in
our understanding of proteasome regulation. Less than a
dozen phosphosites were known to exist on human 26S
proteasome by the early 2000’s, while the number rocketed
to over 300 by 2013 according to PhosphoSitePlus, one of
the most comprehensive phosphoproteomic databases
(www.phosphosite.org). The current tally (by July, 2016) is
455 phosphosites. These include 201 phospho-serine (pS)
sites, 104 phospho-threonine (pT) sites, and 150 phospho-
tyrosine (pY) sites, all but two of which have been detected
by large-scale MS studies. A complete list of all human
proteasome phosphosites is available in Table S1. In the
following discussions, we will primarily rely on information
from PhosphoSitePlus, and refer to the PhosphoGrid
(phosphogrid.org) and PhosphoMouse (https://gygi.med.
harvard.edu/phosphomouse/) databases for phosphoryla-
tions of yeast and mouse proteasomes, respectively.
Proteasome phosphorylations are seen in almost every
large-scale phosphoproteomic dataset. More importantly, the
proteasome is dynamically phosphorylated in a variety of
physiological and pathological processes, including devel-
opment and stem/progenitor cell differentiation (Brill et al.,
2009; Rigbolt et al., 2011; Goswami et al., 2012), cell cycle
(Beausoleil et al., 2006; Dephoure et al., 2008; Nagano
et al., 2009; Olsen et al., 2010; Kettenbach et al., 2011; Guo
et al., 2016), DNA damage response (Matsuoka et al., 2007;
Stokes et al., 2007), stress responses (Um et al., 2010;
Wang et al., 2014), immune signaling (Bose et al., 2001;
Bose et al., 2004; Mayya et al., 2009; Weintz et al., 2010; Wu
et al., 2012), metabolic changes (Bardag-Gorce et al., 2004;
Zhang et al., 2007b; Trost et al., 2012), neuronal activity
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Figure 1. Structural view of a selection of human 26S proteasome phosphosites. Surface (left, middle) and sectional (right)
views of human 26S proteasome (gray) are shown based on high-resolution cryo-EM structures (PDB 5GJR). Phosphosites of
subunits Rpt6 (lemon), Rpn6 (light pink), α7 (smudge), Rpt3 (violet), Rpn2 (salmon), α4 (pale cyan), α2 (wheat), β7 (pale yellow), β1
(pale green) are marked with circles. Sites visible from available structures are highlighted in red, while predicted positions of invisible
sites are represented with a blue star.
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2012; Hamilton et al., 2012; Jarome et al., 2013; Jarome
et al., 2016; Li et al., 2016), hormones and growth factor
signaling (Kim et al., 2009; Pan et al., 2009; Lundby et al.,
2013; Williams et al., 2016), and oncogenesis (Rush et al.,
2005; Rikova et al., 2007; Guo et al., 2008; Luo et al., 2008;
Choudhary et al., 2009; Eang et al., 2009; Iliuk et al., 2010;
Johnson et al., 2012; Trost et al., 2012; Yuan et al., 2013).
Although the functional roles of proteasome phosphorylation
in these processes are largely uncharacterized, increasing
evidence indicates that the 26S proteasome is not a uniform
and static complex acting passively as a “cellular trashcan”.
Rather, the proteasome itself is ﬁne-tuned by reversible
phosphorylation in response to intra- and extra-cellular sig-
nals, which can be a prerequisite or feedback mechanism for
a wide spectrum of cellular events that depend on protea-
some function.
A quick examination of the human proteasome phos-
phorylation data shows that phosphosites have been found
on every subunit. The largest subunit Rpn2 has the most
phosphorylation sites (27) while the smallest subunit Rpn15
has only one. However, no correlation exists between the
number of phosphosites and the size of protein for most of
the subunits. Overall, it appears that the 20S CP and the 19S
base subunits are more frequently phosphorylated than the
19S lid, when the total number of MS detections for each site
(based on the high-throughput, i.e. “HTP” numbers from
PhosphoSitePlus) is taken into account. It should be noted,
though, that more than half of the proteasome phosphory-
lations were detected only once by MS, and only 20% of all
human proteasome phosphosites were observed for more
than 5 times in all the studies combined. On the other hand,
the frequency of MS detection of a proteasome phosphosite
does not directly translate into its stoichiometry or functional
importance, due to vastly different sample sources, puriﬁ-
cation/enrichment methods, detection instruments, and
search databases used by various groups. As illustrated
later in detail, some of the functionally important phospho-
sites have only been observed in a temporally or spatially
restricted manner, demonstrating the intricate nature of
proteasome phosphoregulation.
Of the 455 known phosphosites on human 26S protea-
some, 442 (97.1%) are conserved or semi-conserved (i.e.
Ser/Thr substitutions) in mouse and rat proteasome sub-
units, and 391 sites (85.9% of total) are found in zebraﬁsh.
However, the degree of site conservation drops considerably
to 63.3% in fruit ﬂy (D. melanogaster) and less than 50% in
worm (C. elegans) and yeast (S. cerevisiae). Yeast 26S
proteasome has been shown to be phosphorylated at low
stoichiometry (Wu et al., 2011). The majority of yeast pro-
teasome phosphorylation sites (Kikuchi et al., 2010), if
conserved, are rarely phosphorylated in mammals. These
observations suggest that novel phosphosites emerged
during evolution (especially in vertebrates) as new regula-
tory mechanisms of proteasome function, a general theme
that has been proposed for phospho-signaling (Holt et al.,
2009).
The surrounding sequences of many proteasome phos-
phosites conform to well deﬁned recognition motifs of kina-
ses, such as S/TP (MAPKs and CDKs), R/KxxS/T (AGC and
CaMK families), S/TxxD/E (CK1 and CK2), and S/TxxxS/T
(GSK3). Some of the most frequent motifs found on the
proteasome are summarized in Figs. 2 and S1. Even with
this information, it is generally a challenging task to pinpoint
the kinase(s) for a given site, which has been a major hurdle
toward understanding the regulation and function of protea-
some phosphorylation. Up next, we will focus on functionally
characterized proteasome kinases and phosphatases to
showcase the biological relevance of proteasome
phosphorylation.
PROTEASOME KINASES AND PHOSPHATASES
PKA
Protein kinase A (PKA) was probably the ﬁrst kinase impli-
cated in proteasome phosphorylation. The initial hint was co-
puriﬁcation of a cAMP-dependent kinase activity with the
proteasome complex from bovine pituitaries. This putative
kinase reportedly phosphorylated two proteins of 27–28 kDa,
likely to be 20S subunits (Pereira and Wilk, 1990). Sup-
porting the involvement of PKA in proteasome regulation,
Marambaud et al. showed that the common activator of PKA,
forskolin, stimulated endogenous proteasome activity in
HEK293 cells. Puriﬁed PKA phosphorylated some 28–30
kDa subunits in vitro, leading to evident upregulation of
peptidase activity (Marambaud et al., 1996). These original
ﬁndings have been substantiated by subsequent studies. In
particular, endogenous 20S proteasomes isolated from
murine hearts also contains PKA α (catalytic) subunit as
conﬁrmed by Western blot and MS, and PKA-mediated
in vitro phosphorylation enhances peptidase activities of 20S
proteasomes isolated from both heart and liver (Zong et al.,
2006; Lu et al., 2008). Interestingly, Zong et al. also indicated
the presence of phosphatase PP2A (including its α, β, and γ
subunits) in cardiac 20S complexes, and inhibition of PP2A
by okadaic acid (OA) increased proteasome activity. These
data demonstrate that phosphorylation by PKA positively
regulates the 20S proteasome.
However, when incubated with puriﬁed intact 26S pro-
teasome in vitro, PKA preferentially phosphorylates certain
19S subunit(s) instead of the 20S component (Zhang et al.,
2007a and our unpublished observation). Just like the 20S
CP, the 26S holoenzyme becomes more active upon PKA-
mediated phosphorylation, an effect that can be reversed by
the phosphatase PP1γ (Zhang et al., 2007a). MS analysis
showed that recombinant PKA directly phosphorylates Rpt6
at Ser120 in vitro, while the Ser120Ala mutation blocks this
phosphorylation and signiﬁcantly reduces proteasome
activity in cells (Zhang et al., 2007a). Echoing these results,
Lin et al. reported that disease-causing mutants of Huntingtin
(mHTT) could reduce overall PKA activity, Rpt6-S120
phosphorylation hence proteasome activity, causing a
REVIEW Xing Guo et al.









positive feedback leading to mHTT accumulation (Lin et al.,
2013).
Rpt6-S120 is conserved from yeast to human and is
arguably the best characterized among all proteasome
phosphorylation sites, and yet several studies have con-
vincingly demonstrated that it is in fact targeted by a different
kinase, CaMKIIα (See later for details). Moreover, two
groups have directly challenged PKA as the true Rpt6-S120
kinase (Jarome et al., 2013; Lokireddy et al., 2015). In fact,
Ser120 of Rpt6 is preceded by an arginine residue at the −3
position (R117NDS120), which constitutes a typical RXXS/T
recognition motif shared by AGC kinases (such as PKA) and
CaMKs (such as CaMKIIα). It is possible that PKA phos-
phorylates Ser120 in vitro but not necessarily in vivo. In
Figure 2. Representative sequence motifs of human proteasome phosphosites. All human proteasome phosphorylation sites
were divided into pS, pT, and pY groups and their adjacent sequences were separately analysed with Motif-All. Similar motifs were
combined and sequence logos of the ten most abundant representatives are shown. The X-axis shows amino acid positions with the
phosphosites in the center. The Y-axis is the information content, which takes into account the frequency of amino acid across the
proteome (background frequency) and is therefore a better measure.
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addition, detection of phospho-S120 with a phospho-speciﬁc
antibody against PKA substrates (recognizing the RXXpS/T
motif, Lin et al., 2013) does not establish PKA as the kinase.
Moreover, PKA promotes the association between 19S and
20 proteasomes (See below), while S120 phosphorylation by
CaMKIIα was shown not to affect proteasome assembly
(Djakovic et al., 2009). Finally, in contrast to the wide distri-
bution of PKA in many cell types, detection of endogenous
Rpt6-S120 phosphorylation has primarily been restricted to
neuronal cells, where CaMKIIα is highly enriched. Therefore,
it remains to be determined whether PKA phosphorylates
Rpt6-S120 in vivo at all, or if so, under what circumstances.
Nonetheless, PKA-mediated 26S proteasome activation
and the ensuing beneﬁcial effects on protecting neuronal
cells from toxic protein aggregates have been established
(Myeku et al., 2012; Lokireddy et al., 2015; Myeku et al.,
2016). cAMP signal not only activates PKA but also increa-
ses the association between its catalytic subunit and the
proteasome. This leads to phosphorylation of Rpn6 (but not
Rpt6) at Ser14, shown by Phos-tag SDS/PAGE and con-
ﬁrmed by MS. Rpn6-S14 phosphorylation enhances pro-
teasome ATPase activity and promotes the formation of
doubly capped (30S) proteasome, hence accelerating the
degradation of short-lived proteins (Table 1). The phospho-
mimetic mutant Rpn6-S14D facilitates the clearance of a
variety of aggregation-prone proteins closely associated with
neurological diseases, while the phospho-deﬁcient mutant
Rpn6-S14A does the opposite (Lokireddy et al., 2015).
Importantly, the effect of PKA activation on proteasome
assembly occurs in vivo (Asai et al., 2009; Myeku et al.,
2016). The latter study showed that rolipram (a speciﬁc
phosphodiesterase type 4 inhibitor and PKA stimulator)
activates proteasome in mouse brain and prevents protea-
some impairment by mutant tau at the early stage of
tauopathy, leading to improved cognitive ability (Myeku et al.,
2016). More recently, researchers have demonstrated that
many hormones (e.g. epinephrine and glucagon) and
physiological responses (such as exercise or fasting) that
increase cAMP levels also activate the proteasomes and
stimulate Rpn6-S14 phosphorylation as shown with a
phospho-speciﬁc antibody (personal communication with
A. L. Goldberg). These ﬁndings are of obvious clinical rele-
vance and suggest new approaches to (re)activate the pro-
teasome and halt neurodegeneration. However, cautions
should be taken because Rpn6-S14 phosphorylation also
appears to be upregulated in cancer cells (Gnad et al., 2013;
Mertins et al., 2014) and during T cell activation (Ruperez
et al., 2012), the consequences of which have not been
investigated.
CK2
Similar to PKA, protein kinase CK2 has a ubiquitous
expression proﬁle among tissues and cell types, and is one
of the ﬁrst kinases reported to co-purify with the proteasome
from mammalian sources and phosphorylate distinct α
subunits (Ludemann et al., 1993; Castano et al., 1996;
Mason et al., 1996). Interestingly, CK2 orthologs were shown
to phosphorylate 20S subunits of fungi and plants (Umeda
et al., 1997; Pardo et al., 1998; Murray et al., 2002), sug-
gesting that this may be a conserved and common property
of CK2.
In search for a kinase activity that associates with the 20S
proteasome from human erythrocytes, Ludemann et al.
found that the putative kinase was distinct from PKA (the
only known proteasome kinase then) in that it was insensi-
tive to cAMP but could be effectively blocked by heparin, an
inhibitor of CK2. Western blot analysis conﬁrmed the pres-
ence of CK2 in 20S proteasome preparations, and in vitro
phosphorylation of a speciﬁc 30 kDa subunit could be elim-
inated by immunodepletion of CK2 from the proteasome
sample. However, CK2 phosphorylation did not seem to
affect 20S proteasome activity (Ludemann et al., 1993). A
few years later, two groups independently reported that two α
subunits, α7/PSMA3/C8 and α3/PSMA4/C9, were predomi-
nantly phosphorylated in cells labeled with 32P-orthophos-
phate, and the phosphosites were mapped to serine
residues (Castano et al., 1996; Mason et al., 1996). Indeed,
α7 has an acidic C-terminal tail that contains two conserved
serines (ES243LKEEDES250DDDNM), both of which could
be phosphorylated by CK2 (recognizing S/TXXE/D/pS
motifs) in vitro as shown by mutagenesis studies (Castano
et al., 1996; Bose et al., 2004). Nonetheless, none of these
studies proved that CK2 is the physiological kinase for 20S
phosphorylation.
What is the functional relevance of such phosphoryla-
tions? Rivett’s group demonstrated that α7 and α3 were
phosphorylated in both 20S and 26S proteasomes (Mason
et al., 1996), but they were much dephosphorylated by
interferon gamma (IFN-γ) treatment with a concomitant
decrease of 26S proteasome content and increase in 11S/
PA28-containing proteasomes in cells (Bose et al., 2001). α7
mutants with either S243 or S250 or both sites changed to
alanine seemed to be excluded from 26S complexes.
Therefore, α7 appears to be constitutively phosphorylated to
stabilize the 26S proteasome. Its dephosphorylation follow-
ing IFN-γ signaling promotes the switch to 11S-activated
proteasomes that are important for downstream immune
responses (Rivett et al., 2001; Bose et al., 2004). However,
whether IFN-γ speciﬁcally induces α7 dephosphorylation at
S243/S250 and the underlying mechanism have not been
elucidated.
It is noteworthy that α7-S250 is by far the most frequently
detected proteasome phosphorylation site (found in >900
spectra curated at PhosphoSitePlus). Treating cells with
phosphatase inhibitors Calyculin A and okadaic acid did not
further increase S250 phosphorylation (Mason et al., 1998),
indicating that it is probably constitutive as revealed by a
recent MS study (Gersch et al., 2015). Interestingly,
throughout evolution, the very C-terminal end of α7 is rich in
acidic residues. In S. cerevisiae it also contains three
phosphorylation sites that are important for binding to the
REVIEW Xing Guo et al.










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































proteasome quality control factor, Ecm29 (Wani et al., 2016).
Whether this holds true for human α7 is unknown. In addi-
tion, S250 phosphorylation changes during stem cell differ-
entiation, cell cycle and with exposure to anti-cancer drugs
(Brill et al., 2009; Dulla et al., 2010; Schmidt et al., 2011;
Imami et al., 2012). It is unclear how this happens since CK2
is generally considered to be always active. In fact, there is
even evidence against CK2 since its inhibition actually
increased α7-S250 phosphorylation (Franchin et al., 2015).
Therefore, the regulation and biological function of this
heavily phosphorylated site remain to be rigorously exam-
ined (Table 1).
CaMKIIα
Neuronal synapse formation, maintenance, and plasticity
involve drastic changes in the composition of synaptic pro-
teins, and the UPS plays an essential role in controlling local
protein turnover during these processes (Ehlers, 2003; Bin-
gol and Sheng, 2011). In response to neuronal activity, the
26S proteasome complex not only becomes physically
sequestered in dendritic spines (Bingol and Schuman, 2006)
but also exhibits elevated activity (Djakovic et al., 2009).
Intriguingly, both phenomena depend on the kinase CaM-
KIIα, one of the most abundant proteins in the brain and a
master regulator of synapses.
Patrick and colleagues ﬁrst reported that treating hip-
pocampal neurons with bicuculline (BIC, to upregulate action
potentials) increased proteasome activity while tetrodotoxin
(TTX, an action potential blocker) produced the opposite
effect. BIC-induced proteasome activation in neurons was
abrogated by CaMKII inhibitors, whereas the constitutively
active T286D mutant (mimicking the autophosphorylated
form) of CaMKIIα was sufﬁcient to increase proteasome
activity in both neurons and 293T cells. Puriﬁed CaMKIIα
phosphorylated the aforementioned Rpt6-S120 site in vitro
and was therefore established as a new proteasome-regu-
lating kinase (Djakovic et al., 2009).
Soon after, CaMKIIα was demonstrated to be a PIP
in vivo as it co-puriﬁes with 26S proteasomes from synap-
tosome-enriched fractions of rat forebrain. Autophosphory-
lated CaMKIIα shows better proteasome binding and is both
necessary and sufﬁcient for proteasome redistribution to
dendritic spines upon NMDA stimulation, resulting in efﬁcient
synaptic protein degradation (Bingol et al., 2010). Although
this scaffolding function was shown to be independent of
CaMKIIα kinase activity toward Rpt6-S120, proteasomes
containing the Rpt6-S120D mutant seemed to be more
resistant to detergent extraction in hippocampal neurons
(Djakovic et al., 2012). Therefore, CaMKIIα-mediated Rpt6-
S120 phosphorylation may also contribute to proteasome
tethering at the spines. Functionally, blockade of this phos-
phorylation by the S120A mutation or CaMKIIα inhibition
reduces synaptic activity and prevents activity-induced spine
growth (Djakovic et al., 2012; Hamilton et al., 2012). Fur-
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retrieval increases proteasome activity and Rpt6-S120
phosphorylation in amygdala in a CaMKIIα-dependent
manner. Both pharmacological inhibition of CaMKIIα and
S120A knock-in lead to defects of learning and memory in
rodents (Jarome et al., 2013; Jarome et al., 2016 and per-
sonal communications with G. Patrick), strongly supporting
the physiological signiﬁcance of such phospho-regulation of
the proteasome (Table 1).
DYRK2
The cell cycle is driven by ordered and ﬁnely regulated
proteasomal degradation of many proteins such as cyclins,
cyclin-dependent kinase (CDK) inhibitors, and licensing and
check point factors. As a central regulator of cell cycle, the
26S proteasome itself contains multiple residues that are
phosphorylated at different cell cycle stages (Dephoure
et al., 2008; Nagano et al., 2009; Olsen et al., 2010; Ket-
tenbach et al., 2011). The ﬁrst kinase that has a clear role in
cell cycle-dependent proteasome phosphorylation turns out
to be DYRK2 (Guo et al., 2016), a member of the dual-
speciﬁcity tyrosine phosphorylation regulated kinase family
(Becker, 2012).
Unlike PKA, CK2, and CaMKIIα that were all identiﬁed
with targeted approaches, DYRK2 was discovered in an
unbiased screen for kinases that phosphorylate a particular
site of the proteasome, Rpt3-Thr25 (Table 1). This phos-
phosite was ﬁrst detected in mitotic HeLa cells by MS
(Dephoure et al., 2008) then conﬁrmed in multiple cell types
with a phospho-speciﬁc antibody (Guo et al., 2016). As seen
with Rpt6-S120 and Rpn6-S14, phosphorylation of Rpt3-T25
also upregulates proteasome activity towards peptide and
folded protein substrates in vitro and in cells. Interestingly,
Rpt3-T25 phosphorylation occurs only in actively proliferat-
ing cells, with its level being low in G1 phase but markedly
elevated during S, G2, and M phases of the cell cycle.
CRISPR/Cas9-mediated knock-in of Rpt3-T25A mutation,
which reduces endogenous proteasome activity, causes
marked accumulation of cell cycle inhibitors such as p21Cip1
and p27Kip1 during S-to-G2/M transition and impedes cell
proliferation. This is the ﬁrst example that a phosphorylation
event coordinates proteasome activity with cell cycle pro-
gression (Guo and Dixon, 2016; Guo et al., 2016).
Given the biochemical and biological importance of Rpt3-
T25 phosphorylation, a human kinase cDNA library from the
laboratory of the late Dr. Susan L. Lindquist (Taipale et al.,
2012) was used to screen for the responsible kinase(s). An
unexpected kinase, DYRK2, was found to strongly phos-
phorylate T25 in vitro and in cells, while its disruption by
CRISPR/Cas9 essentially abolished the phosphorylation.
The adjacent sequence of T25 (RPXT) is conserved in ver-
tebrates and is a known substrate motif of DYRK family
kinases (Howard et al., 2014). DYRK2-null cells exhibit
lowered proteasome activity and slowed proliferation, phe-
nocopying Rpt3-T25A knock-in. In keeping with the dynam-
ics of Rpt3-T25 phosphorylation during cell cycle, DYRK2
itself is transcriptionally induced upon S phase entry. This
leads to upregulation of T25 phosphorylation and efﬁcient
proteasomal degradation of key proteins like p21Cip1 and
p27Kip1, which in turn facilitates cell cycle progression (Guo
et al., 2016; Huibregtse and Matouschek, 2016).
As discussed above, proteasome activity can be manipu-
lated in vivo by changing its phosphorylation status, offering
new possibilities for proteasome-oriented therapies. Several
types of cancer are exquisitely dependent on proteasome
activity for survival, including basal-like triple negative (ER−/
PR−/HER2−) breast cancer (Petrocca et al., 2013). Inactiva-
tion ofDYRK2sensitized these cancer cells to theproteasome
inhibitor Bortezomib in vitro, and blockade of Rpt3-T25
phosphorylation signiﬁcantly attenuated their tumorigenecity
in vivo (Guo et al., 2016). In addition,DYRK2 gene is ampliﬁed
in a considerable fraction of cancers (Santarius et al., 2010)
and itsmRNA level negatively correlates with clinical outcome
of breast cancer patients (Guo et al., 2016). Therefore,
simultaneous targeting of DYRK2and the proteasomemaybe
a promising combinatorial approach for treating certain can-
cers, as supported by preliminary data fromongoing research.
PKG
The post-mitotic cardiomyocytes, like neurons, are particu-
larly vulnerable to damaged, misfolded, and aggregated
proteins. With a major role in the clearance of cytotoxic
proteins, the UPS is essential for the health of cardiomy-
ocytes but its function is often impaired in heart disease.
Enhancing the degradative capacity of cardiac proteasomes
may therefore provide a way for heart disease control and
treatment. An attractive strategy appears to be through
activation of protein kinase G (PKG), a key regulator of
cellular functions in the cardiovascular system (Rainer and
Kass, 2016).
PKG is activated by the small-molecule second mes-
senger cyclic guanosine 3’-5’ monophosphate (cGMP).
Sildenaﬁl, a phosphodiesterase 5 inhibitor which raises
cGMP levels, enhanced proteasome activity in neonatal rat
ventricular myocytes, while PKG inactivation caused the
opposite effects (Ranek et al., 2013). Importantly, in vivo
administration of sildenaﬁl effectively reduced protein
aggregation and hypertrophy in cardiac tissues of transgenic
mice expressing CryABR120G, a mutant protein whose mis-
folding causes desmin-related cardiomyopathy. Indirect evi-
dence suggested that PKG may be involved Rpt6 and β5
phosphorylation in cells (Ranek et al., 2013). Although the
phosphorylation sites remain to be elucidated, this study
provides mechanistic insights into the established anti-hy-
pertrophy function of sildenaﬁl and therefore may have pro-
found clinical importance (Gillette and Hill, 2013).
Other Ser/Thr kinases
Multiple lines of evidence suggest that polo-like kinase 1
(Plk1) is a proteasome kinase. Plks are activated during
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G2/M transition of the cell cycle and regulate key events of
mitosis (van de Weerdt and Medema, 2006). Plk1, probably
via its polo-box domain, can directly interact with most 20S
subunits and some 19S subunits (Lowery et al., 2007;
Dephoure et al., 2008). The 20S proteasome has been
shown to be phosphorylated (especially at the α3 and α7
subunits) and activated in vitro by Plk1 pre-treated with OA
or mitotic lysates (Feng et al., 2001). On the other hand, Plk1
inhibitors reduce or block the phosphorylation of several
proteasome subunits (Grosstessner-Hain et al., 2011; Ket-
tenbach et al., 2011; Santamaria et al., 2011). The exact
phosphorylation sites and the function of Plk1-mediated
proteasome regulation in mitosis remain to be determined.
As opposed to the above examples, several other Ser/Thr
kinases appear to negatively regulate proteasome activity.
For example, the p38 MAPK phosphorylates Rpn2-Thr273
upon sorbitol-induced osmotic stress, leading to decreased
peptidase activity of the proteasome without changing its
assembly (Lee et al., 2010b, Table 1). This phosphorylation
also increases with high NaCl treatment (Wang et al., 2014).
Another MAPK, ERK2, could phosphorylate Rpn2-T273
in vitro (Tsai et al., 2015). In brain slices from mouse hip-
pocampal CA1 region, long-term potentiation (LTP) stimula-
tion decreased Rpn2-T273 phosphorylation by an unknown
mechanism (Li et al., 2016), presumably leading to an
increase in proteasome activity as seen with CaMKIIα
activation.
Other stress inducers, such as H2O2 or the DNA topoi-
somerase inhibitor etoposide that signal through the ASK1-
JNK1 pathway, can also inhibit the proteasome. This inhibi-
tion requires ASK1, which can bind the ATPase subunits and
phosphorylate Rpt5, leading to decreased proteasome
ATPase activity hence substrate degradation in vitro and
in vivo (Um et al., 2010). Another possible inhibitory kinase is
AMPK. Several AMPK activators, including AICAR, Met-
formin and A-769662, could downregulate 26S proteasome
activity, while genetic deletion of AMPKα2 did the opposite
(Moreno et al., 2008; Viana et al., 2008; Wang et al., 2010).
However, the mechanisms and physiological meanings of
these regulations have yet to be uncovered.
Abl/Arg and proteasome tyrosine phosphorylation
C-Abl and the related protein Arg (Abl-related gene product)
are multi-functional tyrosine kinases and are so far the only
tyrosine kinases shown to directly phosphorylate and regu-
late the proteasome (Liu et al., 2006; Li et al., 2015). Abl was
found in a yeast two-hybrid screen to interact with the 20S
subunit α4/PSMA7. Both Abl and Arg phosphorylate α4 at
two conserved tyrosine residues, Y106 and Y153 (Table 1).
However, these phosphorylations seem to have opposite
effects on proteasome function. Y153 phosphorylation
reduced proteasome activity in vitro and in cells, whereas
Y106 phosphorylation protected α4 from degradation by the
proteasome. As a result, the 26S holoenzyme was low in
abundance but high in activity in Abl/Arg double knockout
cells, leading to little net change in the overall degradation
capacity as compared to WT cells. Albeit the proteotoxic
effect of oxidative stress appeared more evident in the
absence of Abl and Arg (Li et al., 2015), the physiological
signiﬁcance of α4 tyrosine phosphorylation remains
nebulous.
Except for these studies, almost nothing is known about
the function and regulation of proteasome tyrosine phos-
phorylation. Many tyrosine residues of human 26S protea-
some reported to be phosphorylated are conserved even in
yeast, which is surprising in light of the limited overlap of
proteasome phosphosites between the two species and the
evolutionary reduction of tyrosine phosphorylation in higher
organisms (Tan et al., 2009). Since yeast genome does not
encode conventional tyrosine kinases (Manning et al., 2002)
and yeast proteasome is rarely tyrosine-phosphorylated
(PhosphoGrid), those conserved tyrosine residues presum-
ably play structural rather than regulatory roles. As men-
tioned earlier, the HbYX motif at the C-terminal tails of Rpt2,
3, and 5 are critical for bolting the 19S and 20S particles
together. However, the penultimate tyrosines within this motif
of human Rpt2 and Rpt3 seem to be more frequently
phosphorylated than any other pY site of the 19S RP. Such
phosphorylations would undoubtedly preclude RP-CP inter-
action, therefore must happen on free 19S RP (if they truly
happen in cells), perhaps as a prerequisite or checkpoint for
19S RP assembly and/or 26S proteasome formation.
MS results indicate that pY sites are spread all over the
26S complex and they constitute an astounding 1/3 (150/
455) of all known proteasome phosphosites. Moreover, 11
out of the top 12 most frequently detected proteasome
phosphorylations (i.e. sites with HTP > 100 from Phos-
phoSitePlus) occur on tyrosine residues (Table S1). Such
over-representation of pY in the proteasome complex is, at
ﬁrst sight, quite striking as pY is generally perceived as a
very minor portion of the whole phosphoproteome (Hunter
and Sefton, 1980; Olsen et al., 2006; Sharma et al., 2014;
Bian et al., 2016). However, it should be emphasized that
most proteasome tyrosine phosphorylations were observed
by MS following treating cells with pervanadate (a potent
non-speciﬁc inhibitor of protein tyrosine phosphatases, or
PTPs) and enrichment of peptides with anti-pY antibodies. In
fact, few tyrosines have been found phosphorylated on
endogenous proteasome proteins from mouse tissues
(PhosphoMouse), and afﬁnity-puriﬁed proteasomes from
untreated human cells contain very little pY signal as shown
by Western blot (our unpublished results). Together, these
observations strongly suggest that, although the proteasome
may be constantly phosphorylated by tyrosine kinases, the
modiﬁcation must occur at a low stoichiometry and are very
sensitive to dephosphorylation by PTPs. Identiﬁcation of the
relevant tyrosine kinases and PTPs will shed light on why
proteasome tyrosine phosphorylation happens but is kept
under such tight control.
On the other hand, numerous studies have reported sig-
niﬁcant increases of proteasome tyrosine phosphorylation,
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which invariably took place in cancer cells with aberrant
tyrosine kinase signaling (Rush et al., 2005; Gu et al., 2006;
Rikova et al., 2007; Guo et al., 2008; Luo et al., 2008; Iliuk
et al., 2010; Bai et al., 2012; Drake et al., 2012; Johnson
et al., 2012). Most of the deregulated pY sites locate on 20S
subunits, especially α2, whose Y24, Y57, Y76, and Y101
residues appear to be “hot spots” targeted by oncogenic
tyrosine kinases. Considering the prevalent upregulation of
proteasome activity in various types of cancer (Hoeller and
Dikic, 2009), in-depth understanding of proteasome tyrosine
phosphorylation may provide new insights into cancer
pathogenesis, diagnosis, and treatment.
UBLCP1 and proteasome phosphatases
The generally low stoichiometry of proteasome phosphory-
lations (especially pY) and the necessity of phosphatase
inhibitors for their detection strongly indicate a signiﬁcant
role of dephosphorylation in controlling proteasome func-
tions. However, compared to the kinases, proteasome
phosphatases have been even less investigated. Evidence
exists that treating the proteasome with common phos-
phatases (such as PP1 and PP2A family members) or non-
speciﬁc phosphatases (such as λ-phosphatase, alkaline/
acidic phosphatases) can reduce the peptidase activities
in vitro (Mason et al., 1996; Zong et al., 2006; Zhang et al.,
2007a; Kikuchi et al., 2010; Guo et al., 2011). In addition,
PP2A subunits and Calcineurin subunits have been shown
to be in complex with the 20S proteasome (Zong et al., 2006;
Li et al., 2011; Zhang and Wei, 2011), but their roles in
proteasome regulation are far from clear. At present, the only
physiological proteasome phosphatase that has been func-
tionally characterized is ubiquitin-like domain containing
CTD phosphatase 1 (UBLCP1).
UBLCP1 belongs to the haloacid dehalogenase (HAD)
family of phospho-Ser/Thr phosphatases that consists of at
least seven members in mammals. Unlike founding members
of this family, SCP1 and FCP1, which are known to dephos-
phorylate the C-terminal domain (CTD) of RNA polymerase II
(Pol II), UBLCP1 does not interact with or regulate Pol II.
Instead, it is targeted to the 26S proteasome via its UBL
domain (Guo et al., 2011). In fact, UBLCP1 is the only phos-
phatase in the human phosphatome that contains a UBL
domain, making it the ﬁrst and only known proteasome-resi-
dent phosphatase. Knockdown of UBLCP1 enhances pro-
teasome activity in cells, while in vitro UBLCP1 directly
dephosphorylates multiple subunits of puriﬁed 26S protea-
some and reduces its activity. Therefore, UBLCP1 negatively
regulates proteasome function, in amanner that relies on both
its phosphatase activity and direct interaction with the pro-
teasome. One mechanism for this regulation is that UBLCP1
prevents 19S-20S association (or promotes 26S dissocia-
tion), thereby attenuating the overall proteasome activity (Guo
et al., 2011). However, the exact phosphosites modulated by
UBLCP1 were not identiﬁed.
Another important property of UBLCP1 is that it is a
nuclear protein without a canonical nuclear localization sig-
nal (NLS). Its exclusive nuclear localization is strictly
dependent on a single conserved lysine residue (K44) within
the UBL domain, which is also critical for UBLCP1 binding to
the proteasome. Thus, UBLCP1 selectively downregulates
nuclear proteasome without affecting cytoplasmic protea-
some (Guo et al., 2011). This work, together with previously
mentioned synaptic retention of proteasomes by CaMKIIα
(Bingol et al., 2010; Djakovic et al., 2012), demonstrates
compartmentalized proteasome regulation and highlights the
cellular heterogeneity of proteasomes that is usually masked
by using cell/tissue homogenates (Sha et al., 2011; Schmidt
and Finley, 2014).
Owing to the unique structure of UBLCP1 catalytic
domain (Guo et al., 2011), a small-molecule inhibitor was
identiﬁed from a high-content screen that is both potent and
speciﬁc against this phosphatase. Treating cells with this
inhibitor caused an increase of nuclear proteasome activity,
consistent with UBLCP1 being a negative regulator of
nuclear proteasomes (He et al., 2015). This effect is analo-
gous to that of inhibiting USP14, a proteasome-associated
deubiquitinating enzyme (Lee et al., 2010a), both employing
an “inhibition-of-an-inhibitor” strategy to achieve proteasome
activation. Given the impaired proteasome function in neu-
rodegenerative and heart diseases, these compounds may
represent a different approach than PKA activators (See
above) for therapeutics.
HOW DOES PHOSPHORYLATION MODULATE
PROTEASOME FUNCTION?
In principle, a phosphorylation event can positively or neg-
atively impact any aspect of proteasome function and any
step during its biogenesis. This view has been more or less
proven by available examples from largely isolated studies
as described above. Collectively, phosphorylation can reg-
ulate (i) protein stability and abundance of certain subunits
(Li et al., 2015), (ii) proteasome assembly, stability or com-
position (Satoh et al., 2000; Bose et al., 2004; Guo et al.,
2011; Lokireddy et al., 2015), (iii) subcellular localization of
the proteasome (Benedict and Clawson, 1996; Bingol et al.,
2010; Djakovic et al., 2012), (iv) PIP binding (Wani et al.,
2016), (v) substrate recognition (Satoh et al., 1995; Yuan
et al., 2013), and (vi) enzymatic activities (Mason et al.,
1996; Liu et al., 2006; Zong et al., 2006; Djakovic et al.,
2009; Bingol et al., 2010; Guo et al., 2016).
Phosphorylations often take place at ﬂexible loops and
disordered regions of proteins (Holt et al., 2009), posing a
potential challenge for structural analysis. Indeed, despite
biochemical and functional evidence, no structural basis is
available for any of the proteasome phosphosites, leaving a
big gap in our understanding of how exactly their phospho-
rylations alter proteasome properties. Take DYRK2-medi-
ated Rpt3-T25 phosphorylation as an example, it is located
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near the extreme N-terminus of Rpt3, a highly dynamic
region invisible in all crystal and cryo-EM structures of the
proteasome. However, it is likely tucked under Rpn2 and
regulates the rotation of Rpn2 and 19S lid around the fulcrum
formed by the Rpt3-Rpt6 coiled-coil (Matyskiela et al., 2013).
Such rotation is believed to be coupled with substrate
unfolding and translocation, consistent with biochemical
studies showing that Rpt3-T25 phosphorylation enhances
substrate-stimulated ATPase activity of the proteasome
(Guo et al., 2016). Interestingly, although T25 is not con-
served in yeast Rpt3, the latter has a nearby residue, Thr8,
that has been found to be dynamically phosphorylated dur-
ing cell cycle (L. Huang, personal communication). Despite
that the exact site and (probably) the responsible kinase are
different, it is tempting to postulate that phosphorylation at
the very N-terminus of human and yeast Rpt3 may have
similar functions, therefore might be considered as “func-
tionally conserved”. Such scenario has been observed for
other phosphorylation events (Holt et al., 2009) as well as
other post-translational modiﬁcations (Xu et al., 2013). Fig-
ure 1 illustrates the observed or predicted positions of sev-
eral functionally relevant phosphosites on the high-resolution
cryo-EM structure of human 26S proteasome (Huang et al.,
2016), and their speculated roles in proteasome regulation
are summarized in Table 1. Clearly more biophysical and
structural insights are needed to fully explain the molecular
mechanisms for phosphoregulation of the proteasome.
PROSPECTS
How do we go further in understanding proteasome phos-
phorylation? The simple answer is that we need to go
broader and go deeper. On one hand, previous research on
proteasome phosphorylation has been isolated and mostly
relied candidate approaches. More systematic screens are
needed to identify kinases and phosphatases that regulate
proteasome activity and phosphorylation proﬁle. Libraries of
cDNAs, shRNAs, sgRNAs, and small-molecule inhititors are
readily available for this purpose and have been successfully
used (Chou and Deshaies, 2011; Guo et al., 2016). Knowl-
edge about proteasome kinases and phosphatases is
instrumental because it not only allows for direct manipula-
tion of proteasome phosphorylation for biochemical analysis
in vitro and in vivo, but also helps to elucidate the biological
meaning of proteasome phosphorylation by connecting it
with signaling pathways and cellular activities.
On the other hand, description of proteasome phospho-
rylation in proteomic studies has been superﬁcial and it is
necessary to dig deeper into the function and regulation of
individual events. Phospho-speciﬁc antibodies, site-directed
mutagenesis and targeted MS have been and will still be the
prevalent methods for characterizing the phosphosites. A
high quality phospho-antibody would be particularly useful
for determining the intracellular localization of phosphory-
lated proteasomes, a critical question with little investigation.
It will also facilitate the search for relevant kinases and
phosphatases. Overexpression of proteasome subunits
bearing phosphosite mutations may or may not yield a
change in proteasome activity in cells, since the endogenous
wild-type proteins are usually highly abundant, and epitope-
tagged exogenous mutants may not be fully incorporated
into the proteasome complex. In this sense, homozygous
knock-in of point mutations using gene editing tools such as
CRISPR/Cas9 can unequivocally reveal the functional
requirement of proteasome phosphorylation, as has been
demonstrated (Guo et al., 2016). New methods and instru-
mentation for quantitative MS are needed for more sensitive
and accurate capture of transient, dynamic, and low-abun-
dance phosphorylations.
On a separate note, in addition to serine, threonine and
tyrosine, phosphorylation also occurs on other residues such
as histidine. The recent development of monoclonal anti-
bodies against phospho-histidine has redeﬁned our view of
such modiﬁcations in human cells (Fuhs et al., 2015).
Intriguingly, a considerable fraction of the histidine-phos-
phorylated proteome is comprised of proteasome subunits
(Fuhs et al., 2015). This ﬁnding recalls previously identiﬁed
phosphohistidine residues in 20S subunits (Yano et al.,
1999), and yet the physiological function and regulation of
proteasome histidine phosphorylation are not known.
CONCLUDING REMARKS
All of the above research has vividly demonstrated the
heterogeneity and complexity of the proteasome, and has
shattered the stereotypic view that the proteasome is a
“boring” house-keeping machinery. Reversible phosphory-
lation ﬁne-tunes proteasome activity and adds a new layer of
regulation to proteostasis, the basis of all cellular life. The
exquisite control of conserved phosphosites reﬂects highly
specialized needs for coordinating proteasome function with
speciﬁc physiological activities during evolution, which we
still know very little about. Research in this ﬁeld urgently calls
for advanced experimental systems and tools such as sin-
gle-molecule recording, in situ electron cryotomography,
super-resolution microscopy, quantitative cross-linking MS,
as well as other new biochemical/biophysical methods,
pharmacological agents, antibodies, and animal models
(Pack et al., 2014; Asano et al., 2015; Lu et al., 2015).
Development of these tools will also beneﬁt research on
other aspects of proteasome regulation and on macro-
molecular complexes in general.
Proteasome phosphorylation is not only of biological
signiﬁcance but also clinically relevant. Proteasome inhibi-
tors as anti-cancer drugs cannot distinguish between cancer
cells and normal cells, which, however, often differ drastically
in their phospho-signaling. Therefore, targeting both the
proteasome itself and its modulators deregulated in cancer
cells is expected to increase the efﬁcacy of proteasome
inhibitors, improve drug selectivity, and even partly over-
come drug resistance. Conversely, proteasome activation
can be beneﬁcial in treating neurodegenerative and heart
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diseases, which can be achieved by kinase activators (as in
the case of PKA and PKG) or phosphatase inhibitors (as in
the case of UBLCP1). In-depth understanding of proteasome
phosphorylation will greatly expand the repertoire of bio-
chemicals that can be used for proteasome modulation,
providing more choices for proteasome-based regimens in
the clinic.
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